Anaplastic sarcoma of the kidney ( DICER1 ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ DICER1 Registry
Pediatric Blood & Cancer · 2024-08 · 71 (8)
DOI: 10.1002/pbc.31090 ↗At a glance
Journal article in Pediatric Blood & Cancer, published online on 2024-05-28. Written by Peter J Schoettler and 15 co-authors. Institution: Department of Pediatrics, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: DEAD-box RNA Helicases, Registries, Ribonuclease III, Pulmonary Blastoma. Cited 17 times so far (Crossref); 53 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, Rein in Sarcoma Foundation, National Cancer Institute of the National Institutes of Health.
Abstract (original language)
Background
Anaplastic sarcoma of the kidney (ASK) is a DICER1 ‐related neoplasm first identified as a distinctive tumor type through the evaluation of unusual cases of putative anaplastic Wilms tumors. Subsequent case reports identified the presence of biallelic DICER1 variants as well as progression from cystic nephroma, a benign DICER1 ‐related neoplasm. Despite increasing recognition of ASK as a distinct entity, the optimal treatment remains unclear.
Methods
Individuals with known or suspected DICER1 ‐related tumors including ASK were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry. Additionally, a comprehensive review of reported cases of ASK was undertaken, and data were aggregated for analysis with the aim to identify prognostic factors and clinical characteristics to guide decisions regarding genetic testing, treatment, and surveillance.
Results
Ten cases of ASK were identified in the Registry along with 37 previously published cases. Staging data, per Children's Oncology Group guidelines, was available for 40 patients: 13 were stage I, 12 were stage II, 10 were stage III, and five were stage IV. Outcome data were available for 37 patients. Most (38 of 46) patients received upfront chemotherapy and 14 patients received upfront radiation. Two‐year event‐free survival (EFS) for stage I–II ASK was 81.8% (95% confidence interval [CI]: 67.2%–99.6%), compared with 46.6% EFS (95% CI: 24.7%–87.8%) for stage III–IV ( p = .07). Two‐year overall survival (OS) for stage I–II ASK was 88.9% (95% CI: 75.5%–100.0%), compared with 70.0% (95% CI: 46.7%–100.0%) for stage III–IV ( p = .20). Chemotherapy was associated with improved EFS and OS with hazard ratios of 0.09 (95% CI: 0.02–0.31) and 0.08 (95% CI: 0.02–0.42), respectively.
Conclusion
ASK is a rare DICER1 ‐related renal neoplasm. In the current report, we identify clinical and treatment‐related factors associated with outcome including the importance of chemotherapy in treating ASK. Ongoing data collection and genomic analysis are indicated to optimize outcomes for children and adults with these rare tumors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics and Adolescent Medicine, Division of Hematology-Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
- International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.
- Cancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.
- Research Institute, Children's Minnesota, Minneapolis, Minnesota, USA.
ORCID profiles: Miki Nishitani, Alexander T Nelson, Yoav H Messinger, Douglas B Fair, Shifra Ash, Kenneth S Chen, Kris Ann P Schultz
Funding
- NCI NIH HHS
- Rein in Sarcoma Foundation
- National Cancer Institute of the National Institutes of Health
- Pine Tree Apple Tennis Classic
- Children's Minnesota Internal Research Grant Program
- Cancer Prevention and Research Institute of Texas
Cite
APA
Schoettler, P. J., Smith, C. C., Nishitani, M., Harris, A. K., Nelson, A. T., Watson, D. A., Kamihara, J., Mullen, E. A., Hill, D. A., Messinger, Y. H., Fair, D. B., Kumar, K. A., Dehner, L. P., Ash, S., Chen, K. S., & Schultz, K. A. P. (2024). Anaplastic sarcoma of the kidney ( DICER1 ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ DICER1 Registry. Pediatric Blood & Cancer, 71(8). https://doi.org/10.1002/pbc.31090
Vancouver
Schoettler PJ, Smith CC, Nishitani M, Harris AK, Nelson AT, Watson DA, et al. Anaplastic sarcoma of the kidney ( DICER1 ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ DICER1 Registry. Pediatric Blood & Cancer. 2024;71(8). doi:10.1002/pbc.31090
BibTeX
@article{Schoettler2024,
author = {Schoettler, Peter J and Smith, Caroline C and Nishitani, Miki and Harris, Anne K and Nelson, Alexander T and Watson, Dave A and Kamihara, Junne and Mullen, Elizabeth A and Hill, D Ashley and Messinger, Yoav H and Fair, Douglas B and Kumar, Kiran A and Dehner, Louis P and Ash, Shifra and Chen, Kenneth S and Schultz, Kris Ann P},
title = {Anaplastic sarcoma of the kidney ( DICER1 ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ DICER1 Registry},
journal = {Pediatric Blood & Cancer},
year = {2024},
volume = {71},
number = {8},
doi = {10.1002/pbc.31090}
}
EUVIMED